How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [41] How might treatment of ALK-positive non-small cell lung cancer change in the near future?
    Metro, Giulio
    Bellezza, Guido
    Puma, Francesco
    Chiari, Rita
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (10) : 997 - 999
  • [42] Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer
    Kogita, Akihiro
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Banno, Eri
    Terashima, Masato
    De Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Takeyama, Yoshifumi
    Okuno, Kiyotaka
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 1025 - 1030
  • [43] Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zeng, Qinghua
    Zhang, Xiquan
    He, Shan
    Zhou, Zhiyong
    Xia, Luping
    Zhang, Wenxiong
    Zeng, Lin
    CHEMOTHERAPY, 2022, 67 (02) : 67 - 80
  • [44] Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
    Vavala, Tiziana
    Novello, Silvia
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [45] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
    Yang, X.
    Dong, X.
    Liu, Y.
    Jin, B.
    Wang, J.
    Wang, Y.
    Zhang, Y.
    Zhuo, M.
    Zhao, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S663 - S663
  • [46] Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Siying
    Wang, Ruoyao
    Han, Wei
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [47] Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
    Misawa, Kazuhito
    Nakamichi, Shinji
    Iida, Hiroki
    Nagano, Atsuhiro
    Mikami, Erika
    Tozuka, Takehiro
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Kubota, Kaoru
    Yamaguchi, Hiroki
    Seike, Masahiro
    ONCOTARGETS AND THERAPY, 2023, 16 : 65 - 69
  • [48] Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
    Tang, Hao
    Jin, Longyu
    Zhang, Zhang
    Jiang, Zhibin
    Malik, Zeeshan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
    Watanabe, Satoshi
    Sakai, Kazuko
    Matsumoto, Naoya
    Koshio, Jun
    Ishida, Akira
    Abe, Tetsuya
    Ishikawa, Daisuke
    Tanaka, Tomohiro
    Aoki, Ami
    Kajiwara, Tomosue
    Koyama, Kenichi
    Miura, Satoru
    Goto, Yuka
    Sekiya, Tomoki
    Suzuki, Ryo
    Kushiro, Kohei
    Fujisaki, Toshiya
    Yanagimura, Naohiro
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Saida, Yu
    Yoshizawa, Hirohisa
    Nishio, Kazuto
    Kikuchi, Toshiaki
    CANCERS, 2023, 15 (01)
  • [50] An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
    Schokrpur, Shiruyeh
    Hilburn, Van
    Giustini, Nicholas
    Bazhenova, Lyudmila
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1815 - 1824
12345